ArcticZymes Technologies ASA and the Austrian Centre of Industrial Biotechnology (acib) enters a joint research project to uncover the benefits of salt active nucleases in purification of bionanoparticles (BNP's). ArcticZymes Technologies (AZT) has initiated a collaborative research project with the Austrian Centre of industrial Biotechnology (acib), a globally recognized research center headquartered in Graz, Austria, specializing in industrial biotechnology. Acib has established itself as a leading contributor to scientific advancements in the production and purification of Bionanoparticles (BNPs) utilized in various medical applications including cell and gene therapy, vaccines, and oncolytic treatment.

AZT's salt-active nucleases have demonstrated significant efficacy in enhancing the removal of unwanted DNA from BNPs due to their adaptability to relevant conditions. Through this joint project, AZT and acib will unite their respective expertise in enzymology and BNPs' production and purification to devise innovative methods aimed at enhancing their purity and scalability. The project's anticipated outcomes include comprehensive scientific documentation, which will be disseminated at prominent scientific congresses.

Acknowledging the project's potential impact on human health, the COMET (Competence Centers for Excellent Technologies) program has allocated funding (EUR 100.000) to support this collaborative research initiative. COMET fosters synergies between academic and industrial researchers, facilitating translational research and innovation in the biotechnology sector.